Viewing nowCombinationJanudime Tablets 50/500mg
Sitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
International Pharmaceuticals Co., Ltd.

MFDS item code 202300852 · Approved 2023.03.13 · Insurance code 643705480
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication helps patients with type 2 diabetes control their blood sugar levels by combining sitagliptin and metformin. It is primarily used for patients who also follow dietary and exercise regimens, assisting in effectively improving blood sugar levels. This support allows for more systematic management of diabetes.
The dose of this medicine for antidiabetic therapy should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient’s current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Must Not Take This Medicine). 2. Patients receiving metformin: - The recommended initial dose of this medicine for patients whose blood glucose is not adequately controlled with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) together with the patient’s current metformin dose. - Patients switching to this medicine from concomitant sitagliptin and metformin therapy may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with concomitant metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should take the patient’s blood glucose level and current dose into account. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Studies evaluating the safety and efficacy of switching patients previously treated with other oral glucose-lowering drugs to this medicine have not been conducted. Any change in the treatment regimen for type 2 diabetes may result in changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine must not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Take This Medicine).
This medication is used for diabetes treatment and contains two components. The first component helps to control blood sugar levels but may cause serious allergic reactions or skin disorders in some patients. If these symptoms occur, discontinue the medication immediately and consult a physician. Furthermore, during the use of this medication, inflammation of the pancreas, known as pancreatitis, may occur; therefore, symptoms such as abdominal pain or vomiting should be carefully monitored, and if suspected, medication should be discontinued. The second component is effective in lowering blood sugar but could lead to a dangerous metabolic disorder called lactic acidosis in severe cases; therefore, patients with reduced kidney function or liver disease should not take this medication. This medication is not to be administered to patients with impaired kidney function, those in severe conditions such as acute heart failure or acute myocardial infarction, pregnant or breastfeeding women, or children under the age of 18. Additionally, regular meals and appropriate exercise are required while taking this medication, and attention should be paid to hypoglycemic symptoms. There may be an increased risk of hypoglycemia when taken with other blood glucose-lowering agents. This medication may occasionally cause side effects such as diarrhea, nausea, vomiting, headache, upper respiratory infections, so if symptoms are severe or persist, consult a physician. Discontinue this medication temporarily before and after surgery and resume only after normal kidney function is restored. Excessive alcohol consumption may increase the risk of side effects from this medication, so it is advisable to avoid alcohol while taking it. Regular kidney function and blood tests should be conducted during treatment, and tests for vitamin B12 deficiency may also be necessary. Moreover, this medication contains certain coloring agents, so caution is needed for those allergic to such components. In case of overdose, seek medical attention immediately for appropriate treatment, and if necessary, blood dialysis can be performed to remove the medication.
Anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory tract infection, headache, nausea, vomiting, abdominal pain, nasopharyngitis, peripheral edema, hypoglycemia, severe hypoglycemia, acute renal failure, rash, urticaria, cutaneous vasculitis, arthralgia associated with severe and disability, bullous pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, dyspnea, unstable angina, dizziness, decreased appetite, gastrointestinal disorder, itching, dermatitis, anorexia, weight loss
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container that is well-ventilated, and it is advisable to keep it at a temperature ranging between 1 to 30 degrees Celsius. Proper storage maintains the medication's effectiveness and prevents deterioration.
Bright pink oval film-coated tablet
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
International Pharmaceuticals Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.